|
Name and general classification | Manufacturer or source | Clinical stage | Indication |
|
Akt inhibitors | | | |
SF1126 (RGD peptide + LY294002 a morpholino derivative of quercetin) | Semaphore Pharmaceuticals | Phase 1 | Chronic lymphocytic leukemia |
Perifosine (KRX-0401) | Keryx Biopharmaceuticals, Inc | Phase 2 and Phase 3 | Colorectal cancers; multiple myeloma; other multiple cancer types |
PX-866 | Oncothyreon | Phase 1 & 2 | Solid tumor disease; Glioblastoma |
Triciribine (API-2; TCN-PM; VD-0002) | VioQuest Pharmaceuticals | Phase 1 | p-AKT-positive solid malignancies |
Rapamycin (and analogs) | | | |
Everolimus (RAD001; Zortress; Afinitor) | Novartis Pharma AG | Marketed 2009 | Advanced renal cell carcinoma after failure with sunitinib or sorafenib; subependymal giant cell astrocytoma (SEGA) |
Deforolimus (AP23573; MK-8669; Ridaforolimus) | ARIAD Pharmaceuticals; Merck | Phase 3 (SUCCEED TRIAL) | Metastatic soft-tissue and bone sarcomas |
Sirolimus (Rapamycin; MSR001; Rapamune; Perceiva) | Santen Inc; MacuSight, Inc.Wyeth Pharmaceuticals | November 2010 | Prophylaxis of organ rejection in patients >13 years old receiving kidney transplant |
Temsirolimus (CCI-779; TORISEL) | Wyeth Pharmaceuticals | Marketed 2007 | Advanced renal cell carcinoma |
Dual mTOR inhibitors | | | |
AZD8055 | Astra Zeneca | Multiple Phase 1 and multiple Phase 2 | Advanced hepatocellular carcinoma; advanced solid malignancies and lymphomas |
NVP-BEZ235 | Novartis Pharma AG | | Pancreatic cancer |
WYE-125132 | Wyeth Pharmaceuticals | Multiple Phase 1 and Phase 2 | Advanced malignancies |
Palomid 529 | Paloma Pharmaceuticals Inc. | Phase 1 | Age related macular degeneration (intravitreal and conjunctival administration) |
PKI-179 | Pfizer; Wyeth | Phase 1 | Advanced malignant solid tumors |
PKI-402 | Pfizer | | |
PKI-587 (PF-05212384) | Pfizer | Phase 1 | Incurable cancer |
Natural mTOR inhibitors | | | |
Epigallocatechin gallate (EGCG) (flavonoid polyphenol) | Green tea | Pre-clinical | Pending |
Caffeine | Multiple and varied | Pre-clinical | Pending |
Celastrol | Thunder of God vine (Tripterygium wilfordii) | Pre-clinical | Pending |
Curcumin (diferuloylmethane) | Indian spice turmeric | Pre-clinical | Colon cancer (?) |
Hispidulin (flavonoid molecule) | Artemisia vestita Saussurea involucrate | Pre-clinical | Pending |
Resveratrol | Skin of red grapes | Pre-clinical | Pending |
|